Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. (Q39571564)

13 September 2017

Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. (English)

1 reference

13 September 2017

0 references

0 references

1 reference

10

1 reference

13 September 2017

George B Thornton

21

0 references

Sheila Keating

object named as

Sheila Keating

3

0 references

Adrian V. S. Hill

22

object named as

Adrian V S Hill

1 reference

13 September 2017

Susanna Dunachie

2

0 references

Tamara Berthoud

5

object named as

Tamara Berthoud

1 reference

13 September 2017

11

Ian Poulton

1 reference

13 September 2017

16

Simon Correa

1 reference

13 September 2017

4

Jenni M Vuola

1 reference

13 September 2017

18

Geoffrey Butcher

1 reference

13 September 2017

13

Filip Dubovsky

1 reference

13 September 2017

14

Eveline Tierney

1 reference

13 September 2017

17

Angela Huntcooke

1 reference

13 September 2017

20

Robert E Sinden

1 reference

13 September 2017

Michael Walther

1

1 reference

13 September 2017

Annette Schmidt

6

1 reference

13 September 2017

Carolin Maier

7

1 reference

13 September 2017

Laura Andrews

8

1 reference

13 September 2017

Rikke F Andersen

9

1 reference

13 September 2017

Daniel Webster

12

1 reference

13 September 2017

Pramod Sarpotdar

15

1 reference

13 September 2017

Jack Williams

19

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

13 September 2017

1 reference

13 September 2017

23

1 reference

13 September 2017

7

1 reference

13 September 2017

857-864

1 reference

Malaria. A renewed assault on an old and deadly foe.

13 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Protective Immunity produced by the Injection of X-irradiated Sporozoites of Plasmodium berghei

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Cutting edge: the IgG response to the circumsporozoite protein is MHC class II-dependent and CD1d-independent: exploring the role of GPIs in NK T cell activation and antimalarial responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Conserved repetitive epitope recognized by CD4+ clones from a malaria-immunized volunteer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Hepatitis B core particles as a universal display model: a structure-function basis for development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Malaria transmitted to humans by mosquitoes infected from cultured plasmodium falciparum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Cytotoxic CD4+ T cells from a sporozoite-immunized volunteer recognize the Plasmodium falciparum CS protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

A prime-boost regime that combines Montanide ISA720 and Alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.020

10.1016/J.VACCINE.2004.08.020

7 January 2021

Identifiers

DOI

1 reference

13 September 2017

1 reference